note 17 2014 sales-type leases and financing receivables in april 2017 , in conjunction with the implementation of a new 201cgo-to-market 201d business model for the company's u.s . dispensing business within the medication management solutions ( 201cmms 201d ) unit of the medical segment , the company amended the terms of certain customer leases for dispensing equipment within the mms unit . the modification provided customers the ability to reduce its dispensing asset base via a return provision , resulting in a more flexible lease term . prior to the modification , these leases were accounted for as sales-type leases in accordance with accounting standards codification topic 840 , "leases" , as the non- cancellable lease term of 5 years exceeded 75% ( 75 % ) of the equipment 2019s estimated useful life and the present value of the minimum lease payments exceeded 90% ( 90 % ) of the equipment 2019s fair value . as a result of the lease modification , the company was required to reassess the classification of the leases due to the amended lease term . accordingly , most amended lease contracts were classified as operating leases beginning in april 2017 . the change in lease classification resulted in a pre-tax charge to earnings in fiscal year 2017 of $ 748 million , which was recorded in other operating expense , net . beginning april 1 , 2017 , revenue associated with these modified contracts has been recognized on a straight-line basis over the remaining lease term , along with depreciation on the reinstated leased assets . the company's consolidated financial results in 2018 and 2017 were not materially impacted by the financing receivables remaining subsequent to the lease modification discussed above . note 18 2014 supplemental financial information other income ( expense ) , net .

Table:
( millions of dollars ) | 2018 | 2017 | 2016
losses on debt extinguishment ( a ) | $ -16 ( 16 ) | $ -73 ( 73 ) | $ 2014
vyaire medical-related amounts ( b ) | 288 | -3 ( 3 ) | 2014
other equity investment income | 8 | 3 | 8
losses on undesignated foreign exchange derivatives net | -14 ( 14 ) | -11 ( 11 ) | -3 ( 3 )
royalty income ( c ) | 51 | 2014 | 2014
gains on previously held investments ( d ) | 2014 | 24 | 2014
other | 2014 | 3 | 7
other income ( expense ) net | $ 318 | $ -57 ( 57 ) | $ 11
( a ) represents losses recognized upon our repurchase and extinguishment of certain senior notes , as further discussed in note 15 .
( b ) represents amounts related to the company 2019s 2017 divestiture of a controlling interest in its former respiratory solutions business and the subsequent sale in 2018 of the remaining ownership interest .
the amount in 2018 includes the gain on the sale of the remaining non-controlling interest and transition services agreement income , net of the company's share of equity investee results .
the amount in 2017 represents the company 2019s share of equity investee results , net of transition services agreement income .
additional disclosures regarding these divestiture transactions are provided in note 10 in the notes to consolidated financial statements .
( c ) represents the royalty income stream acquired in the bard transaction , net of non-cash purchase accounting amortization .
the royalty income stream was previously reported by bard as revenues .
( d ) represents an acquisition-date accounting gain related to a previously-held equity method investment in an entity the company acquired. .

Question: what is the range of losses on undesignated foreign exchange derivatives , in millions?
Answer: 11
Calculation: subtract(14, 3)